Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 5INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 58Small Cell Lung Carcinoma 22Carcinoma, Hepatocellular 17Neoplasms 15Lung Neoplasms 14Biliary Tract Neoplasms 12Neoplasm Metastasis 11Breast Neoplasms 11Recurrence 10Squamous Cell Carcinoma of Head and Neck 9Melanoma 9Carcinoma 9Advanced Solid Tumors 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Liver Neoplasms 7Head and Neck Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Lymphoma 5Uterine Cervical Neoplasms 4Neoplasms by Site 4Multiple Myeloma 4Lymphoma, Follicular 4Colorectal Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3

Interventions

Ipilimumab 9pembrolizumab 6Nivolumab 4tremelimumab 3Paclitaxel 3Carboplatin 3spartalizumab 2lenvatinib 2durvalumab 2Doxorubicin 2Bevacizumab 2trastuzumab deruxtecan 1tilsotolimod 1tebentafusp 1osimertinib 1eribulin 1envafolimab 1cemiplimab 1balstilimab 1Vemurafenib 1Vascular Endothelial Growth Factor A 1Standard of Care 1Pemetrexed 1Oxaliplatin 1Docetaxel 1Cisplatin 1Capecitabine 1Axitinib 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Diabetes Mellitus, Insulin-Dependent, 12 × durvalumab × Clear all
NCT03084471 2022-12-22

STRONG

AstraZeneca

Phase 3 Completed
867 enrolled 10 charts

Diabetes Mellitus, Insulin-Dependent, 12

NCT02705482 2019-08-26

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

MedImmune LLC

Phase 1 Completed
58 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡